|
CN109843856B
(zh)
|
2016-05-18 |
2023-05-02 |
米拉蒂治疗股份有限公司 |
Kras g12c抑制剂
|
|
KR20200100632A
(ko)
|
2017-11-15 |
2020-08-26 |
미라티 테라퓨틱스, 인크. |
Ｋｒａｓ ｇ12ｃ 억제제
|
|
US10647715B2
(en)
|
2017-11-15 |
2020-05-12 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
|
IL282916B1
(en)
|
2018-11-09 |
2024-05-01 |
Hoffmann La Roche |
United Cyclic Chemical Compounds and Their Uses in the Treatment of RAS-Mediated Disorders
|
|
CN113382774A
(zh)
|
2019-02-12 |
2021-09-10 |
诺华股份有限公司 |
包含tno155和krasg12c抑制剂的药物组合
|
|
CN112390788A
(zh)
*
|
2019-08-13 |
2021-02-23 |
苏州闻天医药科技有限公司 |
一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
|
|
US20220363681A1
(en)
*
|
2019-08-16 |
2022-11-17 |
Genfleet Therapeutics (Shanghai) Inc. |
Oxo six-membered cyclopyrimidine compound, preparation method and medical use thereof
|
|
CN112390796B
(zh)
*
|
2019-08-19 |
2023-06-27 |
贝达药业股份有限公司 |
Kras g12c抑制剂及其在医药上的应用
|
|
CN112694475A
(zh)
*
|
2019-10-23 |
2021-04-23 |
苏州泽璟生物制药股份有限公司 |
环烷基类和杂环烷基类抑制剂及其制备方法和应用
|
|
JP2022553859A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ｒａｓ阻害剤
|
|
CN115894606A
(zh)
|
2019-11-04 |
2023-04-04 |
锐新医药公司 |
Ras抑制剂
|
|
BR112022008534A2
(pt)
|
2019-11-04 |
2022-08-09 |
Revolution Medicines Inc |
Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras
|
|
CN112851663B
(zh)
*
|
2019-11-12 |
2023-07-18 |
博瑞生物医药（苏州）股份有限公司 |
一种并杂环化合物及其用途
|
|
JP2023505100A
(ja)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
共有ｒａｓ阻害剤及びその使用
|
|
CA3163218A1
(en)
*
|
2019-12-02 |
2021-06-10 |
Shanghai Yingli Pharmaceutical Co., Ltd |
Oxygen-containing heterocyclic compound, preparation method therefor and use thereof
|
|
CA3163338A1
(en)
*
|
2019-12-04 |
2021-06-10 |
Arcus Biosciences, Inc. |
Inhibitors of hif-2alpha
|
|
CN113024544A
(zh)
*
|
2019-12-09 |
2021-06-25 |
武汉誉祥医药科技有限公司 |
一种含氰基并杂环化合物及其用途
|
|
MX2022009025A
(es)
|
2020-01-28 |
2022-10-07 |
Protego Biopharma Inc |
Compuestos, composiciones y métodos para estabilizar la transtiretina e inhibir el plegamiento incorrecto de la transtiretina.
|
|
WO2021169990A1
(zh)
*
|
2020-02-24 |
2021-09-02 |
泰励生物科技（上海）有限公司 |
用于癌症治疗的kras抑制剂
|
|
IL295569A
(en)
|
2020-03-19 |
2022-10-01 |
Arcus Biosciences Inc |
Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
|
|
CA3178129A1
(en)
*
|
2020-04-17 |
2021-10-21 |
Dong-A St Co., Ltd. |
Pyridopyrimidinone derivatives and their use as aryl hydrocarbon receptor modulators
|
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
|
WO2022060583A1
(en)
|
2020-09-03 |
2022-03-24 |
Revolution Medicines, Inc. |
Use of sos1 inhibitors to treat malignancies with shp2 mutations
|
|
US11690915B2
(en)
|
2020-09-15 |
2023-07-04 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
US20240100172A1
(en)
|
2020-12-21 |
2024-03-28 |
Hangzhou Jijing Pharmaceutical Technology Limited |
Methods and compounds for targeted autophagy
|
|
WO2022152313A1
(zh)
*
|
2021-01-18 |
2022-07-21 |
成都百裕制药股份有限公司 |
嘧啶衍生物及其在医药上的应用
|
|
CN113072480B
(zh)
*
|
2021-04-13 |
2022-09-30 |
常州佳德医药科技有限公司 |
一种手性(-)-5-氮杂螺[2.4]庚烷-7-醇、制备方法及应用
|
|
WO2022235870A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
|
AR125782A1
(es)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
|
KR20240013776A
(ko)
*
|
2021-05-28 |
2024-01-30 |
레드엑스 파마 피엘씨 |
Kras 돌연변이 단백질을 억제할 수 있는 피리도[4,3-d]피리미딘 화합물
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
|
|
WO2023009585A2
(en)
|
2021-07-28 |
2023-02-02 |
Protego Biopharma, Inc. |
Transthyretin stabilizing compounds
|
|
TW202327569A
(zh)
|
2021-09-01 |
2023-07-16 |
瑞士商諾華公司 |
包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途
|
|
US20230143938A1
(en)
*
|
2021-10-01 |
2023-05-11 |
Incyte Corporation |
Pyrazoloquinoline kras inhibitors
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
WO2023064857A1
(en)
|
2021-10-14 |
2023-04-20 |
Incyte Corporation |
Quinoline compounds as inhibitors of kras
|
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
|
WO2023154124A1
(en)
*
|
2022-02-09 |
2023-08-17 |
Enliven Therapeutics, Inc. |
Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
|
WO2023199180A1
(en)
|
2022-04-11 |
2023-10-19 |
Novartis Ag |
Therapeutic uses of a krasg12c inhibitor
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2024006379A1
(en)
*
|
2022-06-30 |
2024-01-04 |
Axonis Therapeutics, Inc. |
Methods and compounds for inhibiting mkk7 enzymes
|
|
WO2024040131A1
(en)
|
2022-08-17 |
2024-02-22 |
Treeline Biosciences, Inc. |
Pyridopyrimidine kras inhibitors
|
|
WO2024102421A2
(en)
|
2022-11-09 |
2024-05-16 |
Revolution Medicines, Inc. |
Compounds, complexes, and methods for their preparation and of their use
|